Experienced in Episodic Ataxia with Nystagmus

Dr. Rajesh B. Pahwa

Neurology
The University of Kansas Hospital
Kansas University Physicians Inc
3599 Rainbow Blvd, 
Kansas City, KS 
Accepting New Patients
Offers Telehealth
Experienced in Episodic Ataxia with Nystagmus
The University of Kansas Hospital
Kansas University Physicians Inc
3599 Rainbow Blvd, 
Kansas City, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rajesh Pahwa is a Neurologist in Kansas City, Kansas. Dr. Pahwa and is rated as an Experienced provider by MediFind in the treatment of Episodic Ataxia with Nystagmus. His top areas of expertise are Parkinson's Disease, Movement Disorders, Essential Tremor, Deep Brain Stimulation, and Thalamotomy. Dr. Pahwa is currently accepting new patients.

His clinical research consists of co-authoring 159 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in KS
Hospital Affiliations
Adventhealth Shawnee Mission
Kansas City Orthopaedic Institute
Lmh
University Of Kansas Hospital
Saint Luke's South Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox HealthPlans
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Sunflower Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

KANSAS UNIVERSITY PHYSICIANS INC
3599 Rainbow Blvd, Kansas City, KS 66103
Other Locations
KANSAS UNIVERSITY PHYSICIANS INC
4000 Cambridge St, Kansas City, KS 66160
KANSAS UNIVERSITY PHYSICIANS INC
3901 Rainbow Blvd, Kansas City, KS 66160

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 1 Clinical Trial, Evaluating the Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations
A Randomized, Sham Surgery Controlled, Double-blind, Multi-center, Phase 1 Clinical Trial, Evaluating the Safety of VY-AADC02 in Moderate to Advanced Parkinson's Disease Patients With Motor Fluctuations
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Biological, Other
Study Drug: VY-AADC02
Study Phase: Phase 1
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: CVN424
Study Phase: Phase 2
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
Parkinson's Foundation: PD Generation: Mapping the Future of Parkinson's Disease
Parkinson's Foundation: PD Generation: Mapping the Future of Parkinson's Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 14, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)
A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Drug: Neflamapimod
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
Enrollment Status: Terminated
Publish Date: February 28, 2022
Intervention Type: Drug
Study Drug: BIIB054
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
Enrollment Status: Completed
Publish Date: November 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Enrollment Status: Completed
Publish Date: December 01, 2020
Intervention Type: Drug
Study Phase: Phase 2
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
Enrollment Status: Completed
Publish Date: January 09, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
Enrollment Status: Completed
Publish Date: April 19, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

159 Total Publications

Management of Parkinson's disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching.
Management of Parkinson's disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching.
Journal: Expert opinion on pharmacotherapy
Published: March 26, 2025
Similar Doctors
Distinguished in Episodic Ataxia with Nystagmus
Dr. Richard M. Dubinsky
Neurology
Distinguished in Episodic Ataxia with Nystagmus
Dr. Richard M. Dubinsky
Neurology

Kansas University Physicians Inc

4000 Cambridge St, Suite G600, 
Kansas City, KS 
 (0.4 mi)
913-588-1227
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Dubinsky is a Neurologist in Kansas City, Kansas. Dr. Dubinsky has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Episodic Ataxia with Nystagmus. His top areas of expertise are Huntington Disease, Drug Induced Dyskinesia, Tourette Syndrome, and Tardive Dyskinesia. Dr. Dubinsky is currently accepting new patients.

Advanced in Episodic Ataxia with Nystagmus
Dr. Omar H. Jawdat
Neurology | Nephrology
Advanced in Episodic Ataxia with Nystagmus
Dr. Omar H. Jawdat
Neurology | Nephrology

Kansas University Physicians Inc

3901 Rainbow Blvd, 
Kansas City, KS 
 (0.2 mi)
913-588-3315
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Omar Jawdat is a Neurologist and a Nephrologist in Kansas City, Kansas. Dr. Jawdat and is rated as a Distinguished provider by MediFind in the treatment of Episodic Ataxia with Nystagmus. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Inclusion Body Myositis, Spinal Muscular Atrophy (SMA), and Gastrostomy. Dr. Jawdat is currently accepting new patients.

Advanced in Episodic Ataxia with Nystagmus
Dr. Tekalign A. Burka
Neurology
Advanced in Episodic Ataxia with Nystagmus
Dr. Tekalign A. Burka
Neurology

Kansas University Physicians Inc

4000 Cambridge St, 
Kansas City, KS 
 (0.4 mi)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tekalign Burka is a Neurologist in Kansas City, Kansas. Dr. Burka and is rated as a Distinguished provider by MediFind in the treatment of Episodic Ataxia with Nystagmus. His top areas of expertise are Migraine, Migraine with Brainstem Aura, Hereditary Sensory and Autonomic Neuropathy Type 2, and Congenital Insensitivity to Pain with Anhidrosis. Dr. Burka is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pahwa's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 36 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile